MindMed MM120 GAD Phase 2b Results Breakthrough Therapy 2024

Loading viewer...

investor_presentation

Format: PDF investor_presentation

MindMed presented Phase 2b topline data for MM120, its proprietary lysergide D-tartrate candidate for generalized anxiety disorder, along with ODT pharmacokinetic bridging study results. The presentation highlighted the drug's breakthrough therapy designation and clinical progress as of March 2024.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Mind Medicine MindMed

View all →

MindMed Corporate Presentation August 2024

investor_presentation

47 Pages

Mind Medicine (MindMed) 2020 Corporate Presentation Psychedelic Medicines

investor_presentation

Similar investor_presentations from other companies

Browse all →

Phoenix Motor Inc (PEV) Investor Presentation May 2024

investor_presentation

31 Pages

Phoenix Motor Inc

Affimed Immuno-Oncology Immune Cell Engagers 2016

investor_presentation